Francis Medical's Vanquish System Performs First Commercial Prostate Ablation Procedure in Midwest

Key Takeaways

• Francis Medical’s Vanquish System received FDA 510(k) clearance in November 2025 for prostate tissue ablation
• First commercial procedure using water vapor ablation technology completed in Midwest region
• Company pursuing expanded PMA approval for prostate cancer management based on ongoing VAPOR 2 study data

---

Francis Medical has achieved a significant milestone with the completion of the first commercial Vanquish® Water Vapor Ablation System procedure to ablate prostate tissue in the Midwest region. This breakthrough follows the system’s recent FDA 510(k) clearance received in November 2025.

FDA Clearance and Clinical Evidence

The Vanquish System’s regulatory approval was supported by positive interim follow-up data from Francis Medical’s ongoing VAPOR 2 pivotal study. This clinical trial continues to evaluate the safety and efficacy of water vapor ablation technology for prostate tissue treatment.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Technology and Treatment Approach

The Vanquish Water Vapor Ablation System represents an innovative approach to prostate tissue ablation, utilizing controlled water vapor to target specific tissue areas. This minimally invasive technology offers an alternative treatment option for patients requiring prostate intervention.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Expansion and Future Development

The Midwest procedure marks Francis Medical’s geographic expansion of commercial operations following FDA clearance. The company is strategically positioning the Vanquish System in key regional markets to increase patient access to this advanced ablation technology.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Regulatory Pathway Forward

Francis Medical continues patient follow-up in the VAPOR 2 study to gather long-term outcomes data. This information will support a pre-market approval (PMA) submission for an expanded indication targeting the management of clinically localized prostate cancer, potentially broadening the system’s therapeutic applications.

IntelligenceStrategic Takeaways▾

Francis Medical’s Vanquish System received FDA 510(k) clearance in November 2025 for prostate tissue ablation First commercial procedure using water vapor ablation technology completed in Midwest region Company pursuing expanded PMA approval for prostate cancer management based on ongoing VAPOR 2 study data

Clinical Impact

The successful completion of this first commercial procedure demonstrates the practical implementation of water vapor ablation technology in clinical settings. Healthcare providers now have access to this FDA-cleared system for appropriate patient populations requiring prostate tissue ablation.

The milestone represents Francis Medical’s commitment to advancing minimally invasive treatment options while building clinical evidence through ongoing studies to support expanded therapeutic indications.

---

Frequently Asked Questions

What is the Vanquish Water Vapor Ablation System?

The Vanquish System is an FDA-cleared medical device that uses controlled water vapor technology to ablate prostate tissue through a minimally invasive procedure.

When did the Vanquish System receive FDA approval?

The Vanquish Water Vapor Ablation System received FDA 510(k) clearance in November 2025, supported by positive data from the ongoing VAPOR 2 pivotal study.

What are Francis Medical’s plans for expanded indications?

Francis Medical is collecting long-term follow-up data from the VAPOR 2 study to support a PMA submission for expanded indication in managing clinically localized prostate cancer.

Related coverage

• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
• FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain
• FDA Approves Vertex’s First-in-Class Non-Opioid Pain Drug Journavx